These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 37514957)

  • 1. Advances in saRNA Vaccine Research against Emerging/Re-Emerging Viruses.
    Liu Y; Li Y; Hu Q
    Vaccines (Basel); 2023 Jun; 11(7):. PubMed ID: 37514957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trans-Amplifying RNA Vaccines Against Infectious Diseases: A Comparison with Non-Replicating and Self-Amplifying RNA.
    Zimmermann L; Erbar S
    Methods Mol Biol; 2024; 2786():135-144. PubMed ID: 38814392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccines' New Era-RNA Vaccine.
    Zhou W; Jiang L; Liao S; Wu F; Yang G; Hou L; Liu L; Pan X; Jia W; Zhang Y
    Viruses; 2023 Aug; 15(8):. PubMed ID: 37632102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Importance of RNA-Based Vaccines in the Fight against COVID-19: An Overview.
    Machado BAS; Hodel KVS; Fonseca LMDS; Mascarenhas LAB; Andrade LPCDS; Rocha VPC; Soares MBP; Berglund P; Duthie MS; Reed SG; Badaró R
    Vaccines (Basel); 2021 Nov; 9(11):. PubMed ID: 34835276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trans-Amplifying RNA: A Journey from Alphavirus Research to Future Vaccines.
    Yıldız A; Răileanu C; Beissert T
    Viruses; 2024 Mar; 16(4):. PubMed ID: 38675846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. mRNA Vaccine Development for Emerging Animal and Zoonotic Diseases.
    Le T; Sun C; Chang J; Zhang G; Yin X
    Viruses; 2022 Feb; 14(2):. PubMed ID: 35215994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Production, Characterization, and Assessment of Permanently Cationic and Ionizable Lipid Nanoparticles for Use in the Delivery of Self-Amplifying RNA Vaccines.
    Kairuz D; Samudh N; Ely A; Arbuthnot P; Bloom K
    Pharmaceutics; 2023 Apr; 15(4):. PubMed ID: 37111658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Self-Amplifying RNA: A Second Revolution of mRNA Vaccines against COVID-19.
    Silva-Pilipich N; Beloki U; Salaberry L; Smerdou C
    Vaccines (Basel); 2024 Mar; 12(3):. PubMed ID: 38543952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Self-amplifying mRNA vaccines: Mode of action, design, development and optimization.
    Pourseif MM; Masoudi-Sobhanzadeh Y; Azari E; Parvizpour S; Barar J; Ansari R; Omidi Y
    Drug Discov Today; 2022 Nov; 27(11):103341. PubMed ID: 35988718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Self-amplifying mRNA-Based Vaccine Technology and Its Mode of Action.
    Maruggi G; Ulmer JB; Rappuoli R; Yu D
    Curr Top Microbiol Immunol; 2022; 440():31-70. PubMed ID: 33861374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polyplex nanomicelle delivery of self-amplifying RNA vaccine.
    Chang YH; Lin MW; Chien MC; Ke GM; Wu IE; Lin RL; Lin CY; Hu YC
    J Control Release; 2021 Oct; 338():694-704. PubMed ID: 34509585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new generation of vaccines based on alphavirus self-amplifying RNA.
    Ballesteros-Briones MC; Silva-Pilipich N; Herrador-Cañete G; Vanrell L; Smerdou C
    Curr Opin Virol; 2020 Oct; 44():145-153. PubMed ID: 32898764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incorporation of 5 methylcytidine alleviates innate immune response to self-amplifying RNA vaccine.
    Komori M; Morey AL; Quiñones-Molina AA; Fofana J; Romero L; Peters E; Matsuda K; Gummuluru S; Smith JF; Akahata W; Akiyama H
    bioRxiv; 2023 Nov; ():. PubMed ID: 37961509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of a self-amplifying mRNA reporter vaccine in explant models of broiler chickens.
    Snoeck J; Chiers K; Tam Y; Sanders NN; Garmyn A
    Poult Sci; 2023 Nov; 102(11):103078. PubMed ID: 37801866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Self-Amplifying RNA Approach for Protein Replacement Therapy.
    Papukashvili D; Rcheulishvili N; Liu C; Ji Y; He Y; Wang PG
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete substitution with modified nucleotides suppresses the early interferon response and increases the potency of self-amplifying RNA.
    McGee JE; Kirsch JR; Kenney D; Chavez E; Shih TY; Douam F; Wong WW; Grinstaff MW
    bioRxiv; 2023 Sep; ():. PubMed ID: 37745375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Vitro Transcribed RNA-Based Platform Vaccines: Past, Present, and Future.
    Perenkov AD; Sergeeva AD; Vedunova MV; Krysko DV
    Vaccines (Basel); 2023 Oct; 11(10):. PubMed ID: 37897003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Self-Amplifying RNA Vaccine Candidates: Alternative Platforms for mRNA Vaccine Development.
    Schmidt C; Schnierle BS
    Pathogens; 2023 Jan; 12(1):. PubMed ID: 36678486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymeric and lipid nanoparticles for delivery of self-amplifying RNA vaccines.
    Blakney AK; McKay PF; Hu K; Samnuan K; Jain N; Brown A; Thomas A; Rogers P; Polra K; Sallah H; Yeow J; Zhu Y; Stevens MM; Geall A; Shattock RJ
    J Control Release; 2021 Oct; 338():201-210. PubMed ID: 34418521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases.
    Maruggi G; Zhang C; Li J; Ulmer JB; Yu D
    Mol Ther; 2019 Apr; 27(4):757-772. PubMed ID: 30803823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.